Literature DB >> 23773713

A modified Hassab's operation for portal hypertension: experience with 562 cases.

Yang Liu1, Yiming Li, Jiancang Ma, Le Lu, Li Zhang.   

Abstract

BACKGROUND: Many patients with portal hypertension require surgical treatment each year, and Hassab's operation, or esophagogastric devascularization and splenectomy, is an elective procedure. However, it is difficult to devascularize all the vessels of the upper half of the stomach and distal esophagus when hyperblastosis, edema, extensive vein conglobation, and conglutination are present during the operation. These increase the postoperative risk of repeat bleeding. PATIENTS AND METHODS: We modified Hassab's operation to address the difficulties associated with devascularization in these cases. All consecutive Chinese patients with liver cirrhosis and portal hypertension who underwent the modified Hassab operation in the Second Affiliated Hospital of Xi'an Jiaotong University from September 1995 to December 2010 were included in the present retrospective study.
RESULTS: A total of 562 modified Hassab's operations were performed, and all the emergency operations performed because of bleeding obtained hemostasis. Although the pressure and blood flow of the portal vein decreased slightly after surgery, it was still maintained at a high level. Overall, 21.8% of the patients had complications, and 4.6% of these patients died during the hospitalization period. Within the 12-month follow-up period, the overall improvement rate of varices was 98.5% and the variceal bleeding rate was 1%. The 5-year bleeding rate was 9.7%.
CONCLUSIONS: The modified Hassab operation is an effective procedure for the treatment of portal hypertension. Few early or late complications were observed among the patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Devascularization; Hassab's operation; Modified; Portal hypertension

Mesh:

Year:  2013        PMID: 23773713     DOI: 10.1016/j.jss.2013.05.046

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Prognosis of endotherapy versus splenectomy and devascularization for variceal bleeding in patients with hepatitis B-related cirrhosis.

Authors:  Li Jiang; Hong-Shan Wei; Jia-Li Ma; Ling-Ling He; Ping Li
Journal:  Surg Endosc       Date:  2020-06-05       Impact factor: 4.584

2.  Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis Patients.

Authors:  Xingshun Qi; Guohong Han; Chun Ye; Yongguo Zhang; Junna Dai; Ying Peng; Han Deng; Jing Li; Feifei Hou; Zheng Ning; Jiancheng Zhao; Xintong Zhang; Ran Wang; Xiaozhong Guo
Journal:  Med Sci Monit       Date:  2016-07-19

3.  Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised controlled trial in China.

Authors:  Ruoyang Shao; Zhiwei Li; Jitao Wang; Ruizhao Qi; Qingbo Liu; Weijie Zhang; Xiaorong Mao; Xiaojing Song; Lei Li; Yanna Liu; Xin Zhao; Chuan Liu; Xun Li; Changzeng Zuo; Weidong Wang; Xiaolong Qi
Journal:  BMJ Open       Date:  2020-06-23       Impact factor: 2.692

4.  Elective Splenectomy Combined with Modified Hassab's or Sugiura Procedure for Portal Hypertension in Decompensated Cirrhosis.

Authors:  Ya-Wu Zhang; Feng-Xian Wei; Zhen-Gang Wei; Gen-Nian Wang; Man-Cai Wang; You-Cheng Zhang
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-28

5.  Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution.

Authors:  Ko Oshita; Masahiro Ohira; Naruhiko Honmyo; Tsuyoshi Kobayashi; Eisuke Murakami; Hiroshi Aikata; Yasutaka Baba; Reo Kawano; Kazuo Awai; Kazuaki Chayama; Hideki Ohdan
Journal:  J Gastroenterol       Date:  2020-06-12       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.